Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

Affiliations

• ¹ Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
• ² Certara, Inc., Princeton, NJ, USA.
• ³ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
• ⁴ Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden.
• ⁵ Gilead Sciences, Inc., Foster City, CA, USA.
• ⁶ Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. kirschbrown.whitney@gene.com.